Calendar

The October 5 company announcement schedules Q2 results for October 19, and the company press-release listing shows no intervening Q2 results release as of October 13. Thus the October queue item is not a completed earnings print: an earnings surprise, immediate post-release price reaction and T+3 analyst revisions cannot be assessed. The $61.66 anchor is dated October 12 and is pre-results, not a post-print reaction. Zeros in the sentiment fields denote unavailable measurements, not neutral readings. The deterministic prior is neutral with low evidence quality, warranting a cautious monitoring view. [#PR-EARNINGS-2026-10-05] [Company press releases](https://karooooo.com/press-releases/)

The stock fell from $14.19 on October 7 to $11.23 on earnings day, then closed October 12 at the packet’s $11.40 anchor—about 19.7% below the pre-release close. The reaction has not materially reversed despite a narrower adjusted loss and Med Tech growth. One reported post-print Canaccord Buy/$20 reiteration is not evidence of broad upward revisions; forward-estimate changes were unavailable. Social, options, short-interest and employee measures were not supplied; zeros above mean unavailable, not neutral. [company stock history](https://investors.angiodynamics.com/stock-information/historic-stock-lookup)

The initial reported premarket decline of about 4% reversed: DAL closed marginally higher on October 9 at the packet's $82.17 anchor. The mixed reaction fits strong revenue but weaker earnings and a substantial guidance cut. A report cited adjusted EPS of $1.72 versus a $1.76 estimate, but consensus measures vary, so the guidance reset is the firmer signal. Verified post-print analyst revisions are unavailable; zero-valued sentiment fields indicate missing data, not neutral readings. [Stocktwits report](https://finance.yahoo.com/markets/stocks/articles/delta-cuts-2026-earnings-outlook-142917733.html) [Kiplinger market recap](https://www.kiplinger.com/investing/stocks/stocks-climb-a-wall-of-worry-ahead-of-earnings-stock-market-today)

The earnings follow-up materially improves evidence over the April monitoring baseline, consistent with the deterministic score’s positive directional prior and high thesis-change score. Market validation remains weak: after the October 7 after-close release, LEVI fell from $19.51 at that close to $18.70 on October 9, about 4.2%, while several analysts cut targets. The October 7 trading decline preceded the release and should not be attributed to it. Price weakness and target cuts temper the EPS beat and raised guidance; the apparent refund-driven margin benefit makes Q4 DTC and underlying profitability the decisive checks. No reliable social, options, short-interest or employee measures were supplied. [Price history](https://stockanalysis.com/stocks/levi/history/) [Analyst revisions](https://www.tipranks.com/stocks/levi/forecast)

This T+1 earnings update is mixed-to-negative: AP reported that shares rose about 2% on October 8 following the quarterly beat, even as PepsiCo lowered its annual profit outlook. One reported post-print target cut is available, but broader analyst estimate revisions and whether the initial price reaction holds are not yet established. Social, options-skew, short-interest and employee-score fields are unavailable; their zero placeholders are not measurements. [AP report](https://apnews.com/article/56f06d9d9e470785e094323869e6d695) [Goldman target report](https://www.tipranks.com/news/the-fly/pepsico-price-target-lowered-to-165-from-180-at-goldman-sachs-thefly-news)

The confirmed earnings release was September 29; the packet's October 8 scheduled earnings date does not identify a new company print. Shares closed at $32.90 on September 28, $32.36 on release day, $29.78 on September 30 and $32.28 on October 8. This shows an initial decline and subsequent recovery, but does not establish what caused either move. [Historical closes](https://stockanalysis.com/stocks/intg/history/) Consensus surprise figures, company guidance revisions and reliable post-print analyst target changes were unavailable. The positive deterministic prior reflects stronger operating evidence, but thin coverage and uncertain recurring cash generation warrant a monitoring stance. No social, options, short-interest or employee-sentiment measurements were supplied.